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Abstract
Background The purpose of this study is to inves-
tigate the prevalence of a history of malignancy in
patients with chest pain who were referred for com-
puted tomography angiography as well as the long-
term survival and cardiovascular outcomes, includ-
ing coronary artery disease (CAD) and coronary artery
calcium (CAC) percentiles of cancer survivors. These
data are relevant since it is unknown how cancer sur-
vivors, who underwent cardio-toxic therapies, should
be monitored.
Methods We analysed all patients with chest pain, who
came to the outpatient clinic and underwent com-
puted tomography angiography. The primary study
endpoint was long-term survival. The secondary end-
points included CAD on computed tomography an-
giogram (CTA), CAC percentiles, suspected and con-
firmed malignancy on CTA, and other accidental find-
ings on CTA.
Results Of all 1,892 patients included in the analyses,
133 (7%) had a history of malignancy and 1,759 (93%)
did not. Mortality rates were higher for the cancer
survivors (6.5% vs 20.9% after ten years, p< 0.001).
The multivariable Cox regression model also showed
higher mortality for cancer survivors after ten years
(adjusted hazard ratio 2.48 [95% confidence inter-
val: 1.58–3.90]). CAD did not differ between both
groups. CAC percentiles were higher in cancer sur-
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vivors (p=0.037). Cancer survivors had more sus-
pected malignancies (3.8% vs 0.5%; p= 0.001) and
also more confirmed malignancies on CTA (3.0% vs
0.1%; p< 0.001).
Conclusions Cancer survivors have higher mortality
rates, no difference in CAD on CTA, higher CAC per-
centiles andmore oftenmalignancy on CTA compared
with patients without a cancer history.
Keywords Coronary artery disease · Computed to-
mography angiography · Cancer survivors
Background
Cancer and cardiovascular diseases (CVD) are world-
wide the two most common causes of mortality [1].
Due to improved diagnosis and treatment of cancer,
the survival rate of these patients has increased over
the last decades [2]. However, the treatment of cancer
can cause an increase in cardiovascular morbidity. For
example, a recent study suggests that coronary artery
disease was significantly prevalent among Hodgkin’s
What’s new?
 Patients with chest pain, who are referred for
computed tomography angiography, with a his-
tory of malignancy show higher rates of mortal-
ity.
 Patients with a history ofmalignancy have no dif-
ference in coronary artery disease on computed
tomography angiogram compared with patients
with no history of malignancy.
 History of malignancy correlates with higher
coronary artery calcium percentiles and more
malignant incidental findings on computed to-
mography angiogram.
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lymphoma survivors, who have received cancer ther-
apy, despite asymptomatic clinical presentation in the
presence of life-threatening coronary artery disease
[3]. Asymptomatic coronary artery disease can have
a significant influence on the mortality and morbid-
ity of these patients. Therefore, early diagnosis and
treatment of coronary artery disease is important in
cancer survivors [4]. However, guidelines on screen-
ing cancer survivors are still lacking [5, 6].
In patients with an intermediate risk of coronary
artery disease, computed tomography angiography
should be considered as an alternative to invasive
coronary angiography in the investigation of sus-
pected coronary artery disease [7, 8]. Computed
tomography angiography is an effective, accurate,
and non-invasive tool for diagnosing coronary artery
disease, not only in symptomatic patients, but also
in asymptomatic patients [3]. The cardiac CT scan
is also used for coronary artery calcium (CAC) scor-
ing. Just as computed tomography angiography, CAC
scoring is non-invasive and can be used clinically for
cardiovascular risk assessment and the investigation
of patients with chest pain [9]. Moreover, computed
tomography angiography and CAC scoring have the
ability to depict extra cardiac lesions [10].
The primary aim of this study is to investigate
whether a history of malignancy has an association
with long-term survival in patients with chest pain
referred for computed tomography angiography. The
secondary aim is to explore the association between
history of malignancy and coronary artery disease,
CAC percentiles and ‘accidental’ findings (including
malignancy) on computed tomography angiogram
(CTA). These data are of importance since it is un-
known how patients with a history of malignancy,
who underwent cardio-toxic therapies, should be
monitored [5, 6].
Methods
Study design and population
We performed a retrospective cohort study includ-
ing all adult patients (>18 years) with symptoms of
chest pain, who visited the outpatient clinic between
September 2006 and December 2016 and who were re-
ferred for computed tomography angiography in the
Erasmus MC, UniversityMedical Centre in the Nether-
lands. Data on history of malignancy and the cancer
treatment received were obtained from our electronic
patient system. The exclusion criteria were cases that
lacked data and duplicate cases. According to Dutch
law, this study did not require a written informed con-
sent.
Study endpoints and definitions
The primary study endpoint was long-term survival.
Follow-up data were obtained in 2018. We determined
the patient’s survival status on 11 January 2018 by
contacting the municipal civil registry. The secondary
endpoints included coronary artery disease and cal-
cium scores, malignancy on CTA and accidental find-
ings on CTA. The coronary arteries were divided into
6 separate segments. Significant coronary artery dis-
ease was defined as coronary artery stenosis of >50%.
CAC percentiles were calculated by using the CAC
Score Reference Values web tool by the Multi-Ethnic
Study of Atherosclerosis (MESA) to adjust for age, gen-
der and race [11].
Statistical analyses
Continuous variables are expressed asmean± standard
deviation (SD) values or medians [interquartile range
(IQR)], depending on the distribution, and were com-
pared by Student’s t-test or Mann-Whitney U test.
Normality was tested by the Shapiro-Wilk test. Cat-
egorical variables are expressed as frequencies and
percentages and were compared by chi-squared test
or Fisher’s exact test. The Kaplan-Meier method was
used to evaluate the probability of survival of pa-
tients with and without a history of malignancy over
10 years. The survival curves were compared by the
log-rank test. To investigate whether a history of ma-
lignancy is associated with mortality, the Cox propor-
tional-hazards regression model was used. Variables
were included in the multivariable Cox regression
model, if the p-value was <0.20 in the univariate anal-
ysis. We have used the enter method for the Cox
multiple regression model. All multivariable models
were constructed using the enter method. A two-
tailed p-value of <0.05 was considered to indicate
statistical significance. All statistical analyses were
performed using SPSS statistical software (IBM Corp.
Released 2016. IBM SPSS Statistics for Windows,
Version 24.0. Armonk, NY: IBM Corp).
Results
Study population
Of all 2,482 study cases, 85 were excluded due to
lack of data, 22 cases were duplicates, and 483 pa-
tients, who had come to the outpatient clinic, were
excluded because they had not undergone computed
tomography angiography. Of all 1,892 patients in-
cluded, 133 (7%) had a history of malignancy. (Fig. 1).
Patients with a history of malignancy were signif-
icantly older (median age 61 [53–69] vs 55 [48–62]
years, p< 0.001), were more often diagnosed with
lung disease, i.e. chronic obstructive pulmonary dis-
ease (COPD) or asthma (15.8% vs 10.1%, p= 0.037)
and were more often treated with antiplatelets (14.6%
vs 9.1%, p=0.034) (Tab. 1). Type of malignancy in
history, cancer treatment received and median time
between cancer treatment and computed tomography
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Fig. 1 Flowchart of patients included in the study. MSCTmulti-
slice computed tomography
Table 1 Baseline charac-
teristics
History of malig-
nancy
n= 133
No history of malig-
nancy
n= 1,759
P value
Female gender, n (%) 71 (53.4) 913 (51.9) 0.74
Median age in years [IQR] 61.0 [53–69] 55.0 [48–62] <0.001
Lung diseases, n (%)
COPD/asthma 21 (15.8) 177 (10.1) 0.037
Cardiovascular risk factors, n (%)
Hypertension 60 (45.1) 795 (45.2) 0.99
Hypercholesterolaemia 50 (37.6) 714 (40.7) 0.48
History of cardiac disease 16 (12.0) 173 (9.8) 0.42
History of invasive cardiac intervention 9 (6.8) 94 (5.3) 0.49
Creatinine >120µmol/l 10 (5.5) 82 (3.7) 0.22
BMI >25 90 (68.7) 1,135 (67.6) 0.80
Diabetes mellitus, n (%) 0.70
NIDDM 16 (12) 174 (9.9)
Insulin 7 (5.3) 108 (6.2)
Ever smoker, n (%) 45 (33.8) 503 (28.6) 0.20
Medication, %
ARB 9.5 13.6 0.17
ACE inhibitor 19.7 15.6 0.2
ASA 35 33.5 0.72
Antiplatelet drug 14.6 9.1 0.034
Beta blocker 37.2 35.6 0.70
Calcium antagonist 15.3 14.2 0.71
Diuretic 16.8 18 0.71
MRA 0 0.3 0.53
Statin/cholesterol-lowering medication 46 47.5 0.73
COPD chronic obstructive pulmonary disease, BMI body mass index, NIDDM non-insulin-dependent diabetes mellitus,
ARB angiotensin II receptor blockers, ACE inhibitor angiotensin converting enzyme inhibitor, ASA acetylsalicylic acid,
MRA mineralocorticoid receptor antagonist
Fig. 2 Survival curve of patients with history of malignancy
versus patients with no history ofmalignancy in 10-year follow-
up
angiography are shown in the online Supplementary
Tab. 4.
Primary outcome
During a median follow-up time of 7 [4.3–8.9] years,
141 (7.8%) patients died (all-cause mortality). The
minimal follow-up term for patients without any event
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Table 2 Univariable and multivariable predictors of all-cause mortality at 10 years follow-up
Univariable Multivariable
HR 95% CI P value HR 95% CI P value
Age 1.08 1.07–1.10 <0.001 1.09 1.07–1.11 <0.001
Male gender 1.67 1.19–2.33 0.003 1.70 1.18–2.47 0.004
COPD or asthma 1.95 1.27–3.00 0.002 1.62 1.02–2.58 0.043
History of cardiac disease 2.06 1.31–3.26 0.002 1.62 0.82–3.20 0.17
History of invasive cardiac inter-
vention
1.98 1.09–3.57 0.024 0.93 0.37–2.35 0.87
Diabetes 1.26 1.06–1.51 0.010 1.27 1.05–1.54 0.016
Smoking 1.54 1.10–2.15 0.013 1.79 1.27–1.23 0.002
LVF 2.12 1.04–4.33 0.038 1.17 0.49–2.77 0.73
CAC percentile 1.01 1.01–1.02 <0.001 1.01 1.00–1.01 0.015
History of malignancy 4.27 2.80–6.50 <0.001 2.48 1.58–3.90 <0.001
COPD chronic obstructive pulmonary disease, LVF left ventricular function, CAC coronary artery calcium, HR hazard ratio, CI confidence interval
was 10 years. The survival status of 1,811 patients
was known. The Kaplan Meier survival curve for all-
cause mortality (Fig. 2) showed a significantly bet-
ter long-term survival of patients with no history of
malignancy compared with patients with a history of
malignancy (all-cause mortality rate: 1.1% vs 6.2% at
2 years, 2.3% vs 12.4% at 4 years, 6.5% vs 20.9% at
10 years, overall p< 0.001).
Table 3 CTA results History of malignancy
n= 133
No history of malig-
nancy
n= 1,759
P value
CAD, n (%) 37 (27.8) 540 (30.7) 0.49
LM >50% stenosis, n (%) 1 (0.8) 13 (0.7) 1.00
LAD >50% stenosis, n (%) 20 (15.0) 317 (18.0) 0.39
LCX >50% stenosis, n (%) 10 (7.5) 83 (4.7) 0.15
RCA >50% stenosis, n (%) 19 (14.3) 193 (11.0) 0.24
RCX >50% stenosis, n (%) 7 (5.3) 41 (2.3) 0.076
Bypass graft >50% stenosis, n (%) 0 (0.0) 1 (0.1) 1.00
Triple-vessel disease, n (%) 1 (0.8) 15 (0.9) 1.00
CAC percentilea, median [IQR] 52 [00–88] 35 [00–82] 0.037
CAC scoreb, median [IQR] 18.8 [00–241.3] 2.7 [00–98] 0.003
Accidental findings, n (%) 34 (25.6) 380 (21.6)
Aortic aneurysm, n (%) 0 (0.0) 30 (1.7) 0.27
Abnormal lymph nodes, n (%) 1 (0.8) 17 (1.0) 1.00
Diaphragmatic hernia, n (%) 1 (0.8) 31 (1.8) 0.72
Heart defects, n (%) 5 (3.8) 43 (2.4) 0.38
Liver nodule/cyst, n (%) 0 (0.0) 27 (1.5) 0.25
Lung nodule, n (%) 5 (3.8) 89 (5.1) 0.51
Skeletal abnormalities, n (%) 1 (0.8) 38 (2.2) 0.52
Other lung disorders, n (%) 5 (3.8) 60 (3.4) 0.80
Other, n (%) 7 (5.3) 36 (2.0) 0.016
Suspected malignancy, n (%) 5 (3.8) 8 (0.5) 0.001
Malignancy, n (%) 4 (3.0) 1 (0.1) <0.001
CTA computed tomography angiography, CAD coronary artery disease, LM left main artery, LAD left anterior descending,
LCX left circumflex, RCA right coronary artery, RCX right circumflex, CAC coronary artery calcium
aOut of 1,707 patients
bOut of 1,776 patients
Univariate analysis of the relationship with all-
cause mortality identified an association with age,
male gender, lung disease (COPD or asthma), history
of cardiac disease, history of invasive intervention
for cardiac disease, diabetes, smoking, CAC score,
left ventricular function and a history of malignancy.
In the multivariable analysis, factors independently
associated with all-cause mortality were age, male
gender, lung disease (COPD or asthma), diabetes,
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Fig. 3 Accidental findings
with computed tomography
angiography
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smoking, CAC score and a history of malignancy
(Tab. 2).
Secondary outcomes
Coronary artery disease on CTA and coronary artery
calcium percentiles
Coronary artery disease on CTA did not differ, for
any of the coronary arteries, in both groups. Patients
with a history of malignancy scored higher in CAC
percentiles compared with patients with no history
of malignancy (52 [00–88] vs 35 [00–82], p= 0.037)
(Tab. 3). The median absolute CAC score was also
higher in patients with a history of malignancy com-
pared with patients with no history of malignancy
(18.8 [00–241.3] vs 2.7 [00–98], p=0.003).
Accidental findings on CTA
Of the patients who had undergone computed to-
mography angiography, 349 (18.4%) patients had an
accidental finding on the CTA. As some patients had
multiple accidental findings, a total of 409 (21.6%)
accidental findings were found. Lung nodules were
the most frequent accidental finding (94 lung nod-
ules, 23%) (Fig. 3). The patients with a history of
malignancy had a significantly higher frequency of
suspected malignancy on CTA compared with pa-
tients with no history of malignancy (3.8% vs 0.5%,
p= 0.001). After examining the pathology results,
more malignancies were diagnosed in the patients
with a history of malignancy (3.0% vs 0.1%, p< 0.001).
‘Other’ accidental findings were also more prevalent
in the patients with a history of malignancy (5.3% vs
2.0%, p=0.016). The rest of the categories of acciden-
tal findings on CTA were not significantly different in
both groups (Tab. 3).
Discussion
Interpretation of findings
Current literature shows that cancer survivors are
a subgroup of patients who are, due to the cancer
therapy, at greater risk of developing cardiovascular
disease [12]. Even though there is increasing in-
terest in cardio-oncology, data-driven guidelines on
screening cancer survivors are lacking. This is due
to the small study sizes and low cardiac event rates
over a short period of time [5, 6]. We performed
this study to investigate the long-term outcomes of
cancer survivors. In this study, we analysed the asso-
ciation between cardiovascular disease and a history
of malignancy in a large cohort. Our study shows
that outpatients with a history of malignancy who are
assessed by computed tomography angiography show
no difference in coronary artery disease on the CTA
for any of the coronary arteries and have higher CAC
percentiles and higher mortality rates compared with
patients with no history of malignancy. Furthermore,
accidental findings on the CTA in patients with no
history of malignancy are mostly non-cancerous as
opposed to patients with a history of malignancy.
Studies on childhood or adolescent cancer show
that cancer survivors have higher mortality rates.
However, the studies show different results on all-
cause mortality. Some studies show that the over-
all mortality is comparable to the general popula-
tion, while other studies show that excess mortality is
caused by both cancer and non-cancer causes [13–15].
With the available data we were able to assess long-
term survival, up to 10 years, for cancer survivors. Our
study showed that cancer survivors had a significantly
higher mortality rate in comparison to patients who
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did not have a history of malignancy. Even after ad-
justing, a history of malignancy remained a significant
independent predictor for mortality.
Cancer survivors, who received cancer therapy,
undergo various therapies that are recognised as
causative agents in cardiovascular disease. Some
chemotherapeutic agents have a direct effect on car-
diomyocytes. This involves generation of excess reac-
tive oxygen species, accumulation of metabolites that
disrupt sarcomere structure and function, and mito-
chondrial dysfunction [6]. Radiation therapy causes
activation of an inflammatory cascade, which affects
all of the structural components of the heart, includ-
ing pericardium, myocardium, heart valves, coronary
arteries and capillaries, and conducting system [16].
The impact of these therapies can cause the higher
risk of fatal cardiovascular events among cancer sur-
vivors compared with the general population [17].
In the univariable analysis poorer left ventricular
function was a predictor for mortality. However, in the
multivariable analysis poorer left ventricular function
was not a significant independent predictor. The left
ventricular function was good in 96% of the patients.
This explains why left ventricular was not a strong
predictor of mortality in this study population.
In contrast to our study, a study on CAC and car-
diac radiation doses in breast cancer survivors (BCS)
suggests that there is no correlation between CAC and
BCS treated with radiotherapy [18]. The MESA cohort
study showed that the prevalence of CAC at baseline
was higher in patients diagnosed with cancer dur-
ing the study compared with patients without can-
cer [19]. In our study cancer survivors had signif-
icantly higher CAC percentiles. One factor explain-
ing the higher CAC percentiles is that these patients
were older than the patients with no history of ma-
lignancy, however, we used the MESA web tool to ad-
just the CAC scores for age. Another factor clarifying
the higher CAC percentiles is the radiation therapy
received by 38% of the cancer survivors. CAC is an
expression of atherosclerosis in the coronary arteries.
Local radiation is known to initiate a cascade of events
that is typical of atherosclerosis [16].
Another study on asymptomatic Hodgkin’s lym-
phoma survivors, who underwent radiation, claims
that prevalence of coronary artery disease among
Hodgkin’s lymphoma survivors is high. This study jus-
tifies screening by computed tomography angiogra-
phy in asymptomatic Hodgkin’s lymphoma survivors
who have had mediastinal radiotherapy. Nevertheless,
this study had a very limited population size of 45 pa-
tients [3]. Our study shows that symptomatic patients
show significant coronary artery disease, especially in
the left anterior descending and right coronary artery.
However, it does not suggest any significant difference
between cancer survivors and patients with no cancer
history.
There is still a discrepancy regarding the potential
benefits of reanalysing CTAs for accidental findings.
In our study, resembling current literature, accidental
findings were prevalent in the study population, es-
pecially the lung nodules [10, 20]. Cancer survivors
had significantly more malignant accidental findings.
Of all the suspected malignancies in cancer survivors,
80% was confirmed by pathology. For the patients
with no cancer, 12.5% of the suspected malignancies
were confirmed by pathology. 3% of the cancer sur-
vivors compared with 0.1% of the patients without
cancer showed a malignancy on their CTA. Therefore,
accidental findings on the CTA for patients with no
cancer history are mostly non-cancerous. This is in
line with a study that reported 0.2% malignant find-
ings [21].
There are several limitations to our study that
should be taken into consideration while interpreting
the present results. First, due to the retrospective
observational study design, we cannot prove causal-
ity. Second, we only have data on all-cause mortality,
but to judge cancer screening modalities it would be
interesting to analyse disease-specific mortality. Nev-
ertheless, all-cause mortality is a hard endpoint that
is free from bias. Data on disease-specific mortality
is often less accurate. Furthermore, we did not anal-
yse the effects of cancer therapy. This merits further
research. Strengths of our study include the large
sample size, long follow-up period and the possibility
to carry out extended multivariable analyses.
Conclusion
Our study concludes that patients with a history of
malignancy have higher mortality rates, no difference
in coronary artery disease on the CTA for any of the
coronary arteries and higher CAC percentiles com-
pared with patients with no history of malignancy.
Furthermore, our study implicates that accidental
findings on the CTA for patients with no cancer
history are mostly non-cancerous. However, when
malignancy is found this is significantly more often in
patients with a history of malignancy.
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